Bellevue Life Sciences Acquisition Corp. Unit
BLACU
BLACU was delisted on the 14th of February, 2025.
0 hedge funds and large institutions have $0 invested in Bellevue Life Sciences Acquisition Corp. Unit in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 3 closing their positions.
100% less funds holding
Funds holding: 3 → 0 (-3)
100% less capital invested
Capital invested by funds: $61.3K → $0 (-$61.3K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$55.6K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$116 |
BLACU Hedge Fund Activity: Q1 2025 in Review
0 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Bellevue Life Sciences Acquisition Corp. Unit (BLACU) for Q1 2025, worth a combined $0 — down 100% from $61.3K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of BLACU and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Clear Street, exiting entirely with an estimated $55.6K sold.
- 0 institutional investors held Bellevue Life Sciences Acquisition Corp. Unit (BLACU) as of Q1 2025, down from 3 in Q4 2024.
- Funds reported $0 of Bellevue Life Sciences Acquisition Corp. Unit stock for Q1 2025, down 100% quarter-over-quarter.
- 0 funds opened new Bellevue Life Sciences Acquisition Corp. Unit positions in Q1 2025 and 3 closed out, a net change of -3 holders.
- The largest Bellevue Life Sciences Acquisition Corp. Unit seller in Q1 2025 was Clear Street, an estimated $55.6K sold.
Based on aggregated 13F filings for Q1 2025.